Fig. 4.

Therapeutic efficacy of IL-36γ-armed OV depends on multiple types of immune cells. Peritoneal MC38 tumor-bearing mice were imaged, randomized, and injected i.p. with PBS or 1.0e8 pfu of vvTK-IL-36γ. The mice treated with vvTK-IL-36γ were divided into four groups (n = 7–8) and further treated with PBS, anti-CD4 ab, anti-CD8 Abs, or anti-NK1.1 Abs as described in Methods. Mouse survival was monitored and Kaplan Meier analysis was performed. Statistical analyses: p = 0.025 for vvTK-IL-36γ versus vvTK-IL-36γ + anti-CD4; p < 0.01 for vvTK-IL-36γ versus vvTK-IL-36γ plus anti-CD8; p = 0.06 for vvTK-IL-36γ versus vvTK-IL-36γ plus anti-NK mAb treatment